20/20 HealthCare Partners Collaborates with Roche to Source and Advance BioTech Innovations
AUBURNDALE, Mass., May 28, 2014 /PRNewswire/ — 20/20 HealthCare Partners LLC (20/20 HCP), a global investment group focused on early stage medical technology and life science innovation, is pleased to announce an agreement with Roche, in which they will source and identify novel treatments and/or technologies in the biotech arena. These areas include oncology/immuno-oncology, neurology, infectious diseases, inflammation and ophthalmology. The partnership aims to advance any identified technologies by facilitating collaborations or the formation of new life science companies.
“Through our partnering with Roche, we hope to identify scientific innovations that could lead to novel treatments for patients, thus contributing to better management of serious disease conditions,” said Hillel Bachrach, Managing Partner, 20/20 HCP. “There is significant innovation coming from academia and other research organizations, and we can provide the experience of successfully moving along start-up companies and the capital resources necessary to help advance breakthrough treatments.”
To enhance its relationships with the targeted institutions and to aid in the successful formation of new life science companies, 20/20 HCP has contracted with pharmaceutical and life sciences industry professional Christine Bunt as a 20/20 HCP Venture Partner. Her extensive experience includes the formation and leadership of two life science companies, leading worldwide commercialization for treatments and holding R&D and business development roles with major pharmaceutical companies. Ms. Bunt will lead efforts and serve as a liaison between 20/20 HCP and Roche.
“Joining forces with 20/20 HCP and taking a lead role in the Roche partnership will enable me to leverage my background in advancing groundbreaking innovative treatments for patients,” said Ms. Bunt.
About Christine Bunt
A serial entrepreneur, Ms. Bunt founded and led two life science companies: INTICA Biomedical, focused on personalized medicine/cancer, and TARIS Biomedical, a spin out company out of MIT in the urology field. Previously, Mrs. Bunt was with Merck & Co. in Whitehouse Station, NJ, where she was leading worldwide commercialization for treatments in inflammation, neuroscience and interventional cardiology. Prior to Merck & Co., she held various R&D, business management and commercialization roles at Roche in Basel, Switzerland. She holds degrees in Medical Technology & Immunochemistry (Biochemistry) from the Institute for Hygiene and Infectious Diseases / Medical School of the University of Saarbrucken, Germany. Mrs. Bunt mentors Entrepreneurs/new technology start-ups at the MIT Deshpande Center. She serves on the Board of the Beth Israel Deaconess Medical Center (BIDMC) and on the Advisory Board of the BIDMC Cancer Research Center.
20/20 HealthCare Partners LLC is a global investment group that provides funding and collaboration primarily at the earliest stage of technology and life science innovation. The firm has a long history of creating value by partnering with entrepreneurs and executives in the healthcare community. Through strategic advice, team building, product development and syndicated investment, 20/20 HCA builds and grows companies that positively impact healthcare and improve quality of life. Far beyond the additional of capital the firm provides operational expertise, extended network of contacts and years of industry leadership to introduce portfolio companies to strategic partners, to accelerate the product development cycle and increase company value for further investment, buyout, public offering or other exit.?
SOURCE 20/20 HealthCare Partners LLC